Use of probe drugs as predictors of drug metabolism in humans

Journal of Clinical Pharmacology

Volumn 37, Issue 1 SUPPL., 1997, Pages

  Kivistö, Kari T ^a   Kroemer, Heyo K ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYDEBRISOQUINE; ALFENTANIL; CAFFEINE; CARBON 14; CHLORZOXAZONE; CITALOPRAM; CODEINE; CREATININE; CYCLOSPORIN; CYTOCHROME P450; DAPSONE; DEBRISOQUINE; DEXTROMETHORPHAN; DNA; DRUG METABOLITE; ERYTHROMYCIN; HYDROCORTISONE; MEPHENYTOIN; MIDAZOLAM; MIXED FUNCTION OXIDASE; N HYDROXYDAPSONE; NORTRIPTYLINE; OMEPRAZOLE; PARAXANTHINE; PHENAZONE; RIFAMPICIN; SPARTEINE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONCENTRATION RESPONSE; DEMETHYLATION; DIET; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDROXYLATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LIVER; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTHERN BLOTTING;

EID: 0030897275     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009703700121     Document Type: Article

References (54)

1. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-184.
2. Guengerich FP: Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In: Pacifici GM, Fracchia GN (eds.): Advances in Drug Metabolism in Man. Luxembourg: European Commission. Office for Official Publications of the European Communities; 1995;181-209.
3. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
4. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-955.
5. Rost KL, Roots I: Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-411.
6. Backman JT, Olkkola KT, Neuvonen PJ: Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
7. Fromm MF, Busse D, Kroemer HK, Eichelbaum M: Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology, 1996;24:796-801.
8. Kroemer HK, Eichelbaum M: Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56:2285-2298.
9. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Wooslev RL: Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-791.
10. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990;48:686-693.
11. Goldstein JA, de Morais SMF: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-299.
12. Flockhart DA: Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19. Clin Pharmacokinet 1995;29(suppl 1):45-52.
13. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, Bertilsson L: Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-518.
14. Brockmöller J, Roots I: Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994;27:216-248.
15. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422.
16. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
17. Raunio H, Pelkonen O: Cancer genetics: genetic factors in the activation and inactivation of chemical carcinogens. In: Ioannides C (ed.): Drugs, Diet and Disease: Mechanistic Approaches to Cancer. Volume 1. New York: Ellis Horwood Ltd; 1995;229-258.
18. Eichelbaum M, Bertilsson L, Säwe J, Zekorn C: Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982;31:184-186.
19. Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
20. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL: A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-105.
21. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA: Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci U S A 1988;85:5240-5243.
22. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C: Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-480.
23. Bertilsson L, Dahl M-L, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, et al: Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993;341:63.
24. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome P450 2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-11829.
25. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-520.
26. Kevorkian JP, Michel C, Hofmann U, Jacqz-Agrain E, Kroemer HK, Peraldi MN, et al: Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 1996;59:583-592.
27. Stüven T, Griese E-U, Kroemer HK, Eichelbaum M, Zanger UM: Rapid detection of CYP2D6 poor metabolizer alleles by long distance and multiplex polymerase chain reaction. Pharmacogenetics, 1996;6:417-421.
28. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF: Human cytochrome P-450pa (P-450IA2), the phenacetin 0-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Biochemistry 1989;86:7696-7700.
29. Kalow W, Tang B-K: The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-514.
30. Fuhr U, Rost KL: Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994;4:109-116.
31. Tang BK, Zhou Y, Kadar D, Kalow W: Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994;4:117-124.
32. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW: Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995;39:65-69.
33. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al: Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996;6:159-176.
34. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al: Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-629.
35. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, et al: Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992;294:206-214.
36. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-697.
37. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB: The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992;51:229-238.
38. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB: The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
39. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB: Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-478.
40. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ: The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-129.
41. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
42. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, et al: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992;51:18-23.
43. May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA: The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther 1990;48:619-627.
44. May DG, Porter J, Wilkinson GR, Branch RA: Frequency distribution of dapsone N-hydroxylase, a putative probe for P450 3A4 activity, in a white population. Clin Pharmacol Ther 1994; 55:492-500.
45. Krivoruk Y, Kinirons MT, Wood AJ, Wood M: Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-614.
46. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ: Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
47. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP: Human liver microsomal N-hydroxylation of dapsone by cytochrome P-450 3A4. Mol Pharmacol 1992;41:975-980.
48. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT: Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995;58:556-566
49. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, Watkins PB: P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994;56:253-260.
50. Engel G, Knebel NG, Hofmann U, Eichelbaum M: Identification of human cytochrome P450 enzymes involved in antipyrine metabolism. Clin Pharmacol Ther. 1996;59:613-623.
51. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 1990; 3:566-573.
52. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ: Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995;5:143-150.
53. Kim RB, O'Shea D, Wilkinson GR: Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995;57:645-655.
54. Yamazaki H, Guo Z, Guengerich FP: Selectivity of cytochrome P450 2E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 1995;23:438-440.